Acute myeloid leukemia (AML) with t(8;16)(p11;p13) (t(8;16) AML) has unique clinico-biological characteristics, but its microRNA pattern is unknown. We analyzed 670 microRNAs in seven patients with t(8;16) AML and 113 with other AML subtypes. Hierarchical cluster analysis showed that all t(8;16) AML patients grouped in an independent cluster. Supervised analysis revealed a distinctive signature of 94-microRNAs, most of which were downregulated, including miR-21 and cluster miR-17-92. The mRNA expression analysis of two known transcription factors of these microRNAs (STAT3 and c-Myc, respectively) showed significant downregulation of STAT3 (P ¼ 0.04). A bioinformatic analysis showed that 29 of the downregulated microRNAs might be regulated by methylation; we treated a t(8;16) AML sample with 5-aza-2 0 -deoxycytidine (5-AZA-dC) and trichostatin A and found that 27 microRNAs were reexpressed after treatment. However, there was no difference in methylation status between t(8;16) and other AML subtypes, either overall or in the microRNA promoter. Cross-correlation of mRNA and microRNA expression identified RET as a potential target of several microRNAs. A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195. In conclusion, t(8;16) AML harbors a specific microRNA signature that is partially epigenetically regulated and targets RET proto-oncogene.
INTRODUCTION
Acute myeloid leukemia (AML) with t(8;16)(p11;p13) (t(8;16)AML) is an infrequent leukemia subtype with characteristic clinical features, including presentation as therapy-related AML, coagulation disorder, frequent extramedullary involvement and poor prognosis. t(8;16)AML blast cells exhibit a myelomonocytic stage of differentiation and frequent hemophagocytosis. 1, 2 Translocation (8;16)(p11;p13) fuses MYST histone acetyltransferase 3 (MYST3, also known as MOZ) on chromosome 8p11 with CREB-binding protein (CREBBP, previously known as CBP) on chromosome 16p13. 3 Both MYST3 and CREBBP encode proteins with histone acetyltransferase activity. 3, 4 MYST3 acts as coactivator of several transcription factors related to hematopoiesis, such as RUNX1, PU.1 and NF-kB. 5, 6 CREBBP is a transcriptional coactivator of some hematopoietic transcription factors, 7, 8 interacts with NF-kB and p53, 9 and has an essential role in hematopoietic stem cell stemness regulation. 6 Recently, structural alterations that lead to inactivation of CREBBP have been observed in several lymphoma subtypes 10 and in acute lymphoblastic leukemia.
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Although the precise pathogenic pathways of t(8;16) AML are mostly unknown, one of the essential mechanisms underlying the disease may be the disruption of several hematopoietic pathways owing to the interaction of the MYST3-CREBBP chimeric protein with several key transcription factors. 12 Interestingly, t(8;16) AML harbors a specific gene signature consisting in the overexpression of several homeobox genes (HOXA9, HOXA10 and HOX cofactor MEIS1), PRL and RET proto-oncogene 1,2 and the underexpression of CCND2 and members of the JAK-STAT pathway STAT3 and STAT5A/B. RET proto-oncogene encodes a tyrosine kinase that transduces signals for cell growth and differentiation. RET mutations have been associated with papillary thyroid carcinoma and multiple endocrine neoplasia type IIA and IIB. 13 In addition, RET overexpression is highly characteristic of t(8;16) AML. 1, 2 MicroRNAs (miRNAs) are small non-coding RNAs (22) (23) (24) nucleotides in length) that negatively regulate mRNA translation by binding to 3 0 -UTR of the target mRNA. 14 miRNAs have an important regulatory role in most biological processes, including development, regulation of cell proliferation and apoptosis, and stem cell self-renewal and differentiation. [14] [15] [16] Moreover, their expression is altered in cancer, where they can function as both oncogenes and tumor suppressor genes. [17] [18] [19] Their expression is regulated by transcription factors and by epigenetic mechanisms such as histone acetylation and methylation of the CpG islands in the promoter region of the gene. [20] [21] [22] miRNA deregulation has also been shown to contribute to the leukemogenic process, and in fact, distinctive miRNA profiles have been identified in several AML subtypes. 12, 23, 24 To date, however, no specific miRNA signature has been described for t(8;16) AML.
In order to further examine the role of miRNAs in t(8;16) AML, we have characterized the miRNA expression profile of the disease and have assessed the role of RET as a target of miRNAs associated with t(8;16) AML.
MATERIALS AND METHODS
Patients, cell samples and RNA isolation A total of 117 patients diagnosed with AML at Hospital Clinic of Barcelona during the period 1994-2009 were included in the study, together with three t(8;16) AML samples from other institutions (Hospital Tor Vergata, Rome; Guy's Hospital, London; Hospital Vall d'Hebron, Barcelona). AML diagnosis and classification was based on accepted FAB or WHO criteria, depending on the year of diagnosis. 25, 26 The main characteristics of patients, including FAB classification, are summarized in Table 1 . The availability of cytogenetic and molecular information on NPM1 and CEBPA mutational status in all these patients allowed us to reclassify them following the WHO 2008 criteria (Supplementary Table S1 ).
Samples were obtained from bone marrow aspirates in 106 patients and from peripheral blood with a minimum blast infiltration of 60% in 14 patients. Mononuclear cells were purified by Ficoll density gradient centrifugation and total RNA was isolated using Trizol reagent according to the manufacturer's protocol (Invitrogen, Paisley, UK). In addition, CD34 þ cells from the bone marrow of three healthy donor subjects were purchased from AllCells (Emeryville, CA, USA). All patients provided their written informed consent in accordance with the Declaration of Helsinki, and the Ethics Committee of Hospital Clínic of Barcelona approved the study.
Molecular analysis
Gene rearrangement of RUNX1/RUNXT1 and CBFb/MYH11 in core-binding factor AML, PML/RARa rearrangement in acute promyelocytic leukemia, and mutations of NPM1, CEBPA, and FLT3 genes were analyzed following standard methods. In addition, MYST3/CREBBP rearrangement in t(8;16) AML was confirmed by a previously reported method. 27 miRNA profiling miRNA profiling using a multiplex real-time quantitative reverse transcription (RT)-PCR strategy was performed using TaqMan Array Human MicroRNA Set Cards v2.0 (Applied Biosystems, Foster City, CA, USA). This method is based on a multiplexing RT-PCR method for the detection 670 mature human miRNAs. RT reactions of 4.50 ml contained: 0.80 ml of 10 RT buffer (Applied Biosystems), 0.2 ml dNTPs (100 mM each), 1.5 ml multiscribe reverse transcriptase (50 U/ml ), 0.10 ml RNase inhibitor (20 U/ml), 0.80 ml Megaplex RT primers (10 Â ), 0.90 ml of MgCl 2 (20 U/ml) and 500 ng of total RNA. RT reactions were incubated in a PTC-100 thermocycler for 2 min at 16 1C and 1 min at 42 1C for 40 cycles, 1 s at 50 1C and 5 min at 85 1C, and then held at 4 1C. Real-time quantitative PCR reactions were performed on an ABI 7900 HT Sequence Detection System (Applied Biosystems) and contained 450 ml of TaqMan Universal PCR Master Mix No Amperase (2 Â ) (Applied Biosystems), 6 ml Megaplex RT product and 444 ml nuclease-free water.
Normalization and filtering of miRNA data Relative miRNA expression was calculated using the 2 À DDCt method. Normalization was performed with RNU48, based on preliminary analyses comparing the stability of RNU6B, RNU24, RNU43, RNU44, RNU48 and MammU6; RNU48 had the lowest variability of expression in the miRNA expression patient data set (Supplementary Figure S1 ) and was therefore used in this study. As calibrator sample, we used the mean miRNA value of the CD34 þ control samples. All miRNAs that expressed o10% or with an unreliable quantification were excluded from further analysis, leaving a set of 387 miRNAs. mRNA expression analysis cDNA was synthesized from total RNA using TaqMan Reverse Transcription Reagent Kit (Applied Biosystems). TaqMan Gene expression assays (Applied Biosystems) were used to determine mRNA levels of cMyc (Hs00905030_m1), STAT3 (Hs01047980_m1) and p53 (Hs01034249_m1). GUSB gene (Hs00939627_m1) was used as housekeeping gene. Real-time PCR was performed in the ABI Prism 7500 Sequence Detection System (Applied Biosystems). All samples for each gene were run in triplicate.
Cell culture and treatment with 5-AZA-dC and trichostatin A (TSA)
The K562, HL-60 and TPH-1 cell lines were obtained from the DSMZ (German Collection of Microorganisms and Cell Cultures). Cells were grown in RPMI 1640 containing 10% fetal bovine serum and penicillinstreptomycin (Invitrogen, UK). Cryopreserved blasts from one t(8;16) AML patient were grown in StemSpan Serum-Free Expansion Medium with StemSpan CC-100 cytokine cocktail (StemCell Technologies, Sirocco, France) to a final concentration of 100 ng/ml recombinant human Fms-like tyrosine kinase 3 ligand, 100 ng/ml recombinant human stem cell factor, 20 ng/ml recombinant human interleukin-3 and 20 ng/ml recombinant human interleukin-6.
Only one t(8;16) AML patient had available cryopreserved cells for treatment with 5-AZA-dC (decitabine) and TSA. This patient sample was treated for 72 h with 5-AZA-dC (2 mM dissolved in dimethyl sulfoxide) (SigmaAldrich, St Louis, MO, USA) with drug replacement every 24 h. For TSA (Sigma-Aldrich) experiments, TSA (250 nM; dissolved in dimethyl sulfoxide) was added for the final 12 h of the 72 h 5-AZA-dC treatment period.
Global quantification of DNA methylation
About 200 ng of genomic DNA were used for quantification of global DNA methylation using the Methylamp Global DNA Methylation Quantification Kit (Epigentek, New York, NY, USA). The methylated fraction of DNA was recognized by a 5-methylcytosine antibody and quantified through an enzyme-linked immunosorbent assay-like reaction included in this kit.
Semi-quantitative DNA methylation analysis of miRNA genes Genomic DNA for methylation analysis of five t(8;16) AML patient samples and nine other cytogenetic AML samples was extracted using DNEasy Blood and Tissue Kit (Qiagen, Valencia, CA, USA) and treated with RNAse A(Qiagen) prior to methylation analysis. The analysis of promoter methylation of 24 genes encoding mature miRNAs was performed using the Human Cancer miRNA Genes EpiTect Methyl Signature qPCR Arrays (Qiagen). This method allows a semi-high throughput DNA methylation profiling based on the detection of remaining input DNA after cleavage with a methylationsensitive and/or methylation-dependent restriction enzyme.
RET 3 0 -UTR cloning
The 3 0 -UTR region of the RET gene sequence was amplified using primers with SgfI (forward) and PmeI (reverse) restriction sites (underlined): Forward primer 5 0 -GCGATCGCGCGGCAAAATTAATGGACAC-3 0 and reverse primer 5 0 -GTTTAAACTCTGTTGTTTCCAACTAGAATGTT-3 0 . PCR products were ligated into a pCR-XL-TOPO vector from TOPO XL PCR Cloning Kit (Invitrogen, Breda, NL, USA) and transformed into TOP10F 0 -competent cells (Invitrogen, UK). Using SgfI (Promega, Madison, WI, USA) and PmeI (New England Biolabs, Hertfordshire, UK) endonucleases, the insert was cut out, purified, and ligated into the 3 0 UTR of Renilla-luciferase in the psiCHECK2 vector (Promega). This vector also contains a firefly luciferase gene used to normalize for transfection efficiency. The constructs were sequenced to check for the proper insert.
Pre-miRNA transfection and luciferase assay The K562 cell line was transfected using Lipofectamine 2000 (Invitrogen, UK) with 1.2 mg of the modified psiCheck2 vector containing the RET 3 0 -UTR region and with 500 nM of pre-miRNA Precursor or pre-miR Negative Control #2 (Ambion, Applied Biosystems). Pre-mir-135a, which has no complementary sequences to the 3 0 -UTR region of RET gene, was included as a negative control. The Renilla-luciferase and firefly luciferase activity was measured at 24 h after transfection with the Promega Dual luciferase reporter assay system (Promega) in an Orion II microplate luminometer (Berthold Detection Systems GmbH, Pforzheim, Germany). The transfection efficiency was normalized with the firefly luciferase gene. Hierarchical clustering was performed using Pearson squared correlation and average linkage. To identify miRNAs with significant differential expression between AML subgroups, two multivariate permutation tests were performed: significance analysis of microarrays and Student's t-test based on multivariate permutation (with random variance model). Differences between miRNAs were considered statistically significant if the P-value was o0.001 (t-test) or false discovery rate o0.1% (significance analysis of microarray).
In order to identify miRNA targets, we used the RmiR package (Bioconductor version 2.6; http://www.bioconductor.org/Bioconductor) to crosscorrelate the miRNA expression data from the present study with our previous findings on the gene expression signature in the same patient samples, 1 based on the predicted targets from TargetScan (http://www. targetscan.org/) and Pictar (http://pictar.mdc-berlin.de/) databases. For this cross-correlation analysis, we used the miRNA expression data from the four t(8;16) AML patients from the present study, and the mRNA expression data of a selection of 46 genes were obtained using TaqMan Low Density Arrays (Applied Biosystems). These 46 genes had been selected on the basis of their differential expression in t(8;16) AML or their oncogenic potential in leukemia. (Table 2 ). An analysis of varience analysis including the main AML cytogenetic subtypes confirmed these differentially expressed miRNAs (data not shown). Interestingly, the downregulated t(8;16) AML signature included tumor suppressor miRNAs (let-7 family, miR-34a, miR-15a, miR-26a/b and miR-125b), miRNAs regulating hematopoiesis (miR-142 and miR-223), miRNAs targeting DNA methyltransferase genes (miR-29b, miR-148, miR-143 and miR-21) and miRNAs widely described in the tumorigenesis process (cluster miR-17-92 and paralogs and miR-21). These findings were further validated in a partial subset of eight miRNAs (Supplementary Figure S2) . In order to rule out the possibility that the t(8;16) AML miRNA profile was a consequence of the monocytic differentiation stage of this subtype, we compared the miRNA expression of t(8;16) AML with that of 53 AMLs with a monocytic phenotype (namely, M4 and M5 of FAB classification) and found a 47-miRNA signature, which differentiated t(8;16) AML from monocytic AMLs. Interestingly, 21 of the 47 miRNAs in this signature overlapped with the t(8;16) AML 94-miRNA signature (Supplementary Figure S3) .
Transcriptional regulation of the t(8;16) AML miRNA signature The transcription of several miRNAs in the signature has been shown to be regulated by key genes such as STAT3, c-Myc and p53. The oncogenic miRNAs miR-21 and cluster miR-17-92, which are usually overexpressed in other cancers, were underexpressed in the t(8;16) AML 94-miRNA signature. To further investigate this issue, we analyzed the expression of the known transcription factors of miR-21 and cluster miR-17-92 (STAT3 and c-Myc, respectively) in seven t(8;16) AML patients and 36 patients with other AML cytogenetic subtypes. STAT3 mRNA levels were significantly downregulated in the t(8;16) AML patients (P ¼ 0.04). Analysis of varience analysis yielded different gene expression profiles among groups (P ¼ 0.005) (Supplementary Figure S3) . There was a non-significant difference of cMyc expression levels between the t(8;16) AML and other AML subtypes (data not shown). Several miRNAs downregulated in the t(8;16) AML miRNA signature, such as miR-34a, are known to be regulated by p53. However, the quantification of p53 mRNA showed no statistical differences between the t(8;16) AML and the remaining samples (data not shown).
Epigenetic regulation of the t(8;16) AML miRNA signature In order to elucidate the potential mechanisms of the downregulation of 90 miRNAs of the t(8;16) AML miRNA signature, we examined the presence of CpG islands in the promoter regions of the miRNA genes and in the promoter regions of the genes where the intronic miRNAs are embedded. The bioinformatic analysis showed that 29 downregulated miRNAs could potentially be regulated by methylation. Therefore, we used two different approaches: the global methylation analysis of genomic DNA and the treatment of patient samples with 5-AZA-dC and TSA. Firstly, when we compared three t(8;16) AML patient samples with 18 non-t(8;16) AML samples, we did not observe any statistical differences in the overall pattern of methylation (Figure 2a) . However, when we treated a t(8;16) AML sample for 72 h with 5-AZA-dC, 14 miRNAs were re-expressed more than twofold change. Interestingly after treatment with 5-AZA-dC and TSA, 27 of 29 miRNAs were re-expressed more than 2 fold change after treatment (Supplementary Figure S4) . These results indicate that the miRNA downregulation may be explained in part by epigenetic mechanisms.
Semi-quantitative DNA methylation analysis In order to further examine the potential role of methylation as a mechanism of downregulation of some of the miRNAs in our t(8;16) AML signature, we analyzed the CpG island DNA methylation profiles of 12 miRNA genes corresponding to 15 mature miRNAs of our signature included in the Human Cancer miRNA Genes EpiTect Methyl Signature qPCR Arrays. We observed that four miRNA genes, corresponding to seven mature miRNAs, showed more than 40% hypermethylation (Figure 2b) : MIRLET7G, MIR1, MIR 218 and MIR23B (miR-23b, miR-24-1, miR27b). Of note, MIR23B showed a remarkable hypermethylation. Nonetheless, when we compare the miRNA promoter methylation in the t(8;16) AML samples with that of the nine samples of other AML subtypes, we found no significant differences. However, the hierarchical cluster analysis taking into account the percentage of miRNA promoter hypermethylation (Figure 2c ) showed that the t(8;16) samples were closer to high-risk cytogenetics samples than good-prognosis cytogenetics samples.
RET is a target of the t(8;16) AML miRNA signature In order to identify potential targets of the miRNAs in the t(8;16) AML miRNA signature, we cross-correlated the miRNA expression with gene expression data in the same t(8;16) AML patient samples. We found an inverse correlation of miR-130a and miR130b with HOXA3 (r 2 ¼ À 0.5 and À 0.8, respectively), of miR-1 and miR-23b with MEIS1 (r 2 ¼ À 0.62), and of miR-15b, miR-195 and miR-218 with RET (r 2 ¼ À 0.92, À 0.58 and À 0.87, respectively). As miRNAs targeting RET showed the highest correlation, we focused further analyses on RET target validation. Strikingly, further analysis of the 3 0 UTR regions of RET with TargetScan v5.1 showed the presence of target sites for nine miRNAs of the signature. In addition to miR-15b, miR-195 and miR-218, RET was a putative target of miR-15a, miR-34a, miR-424, miR-128 and miR-27a/b (Supplementary Figure S5) . Interestingly, RET harbors two putative binding sites for miR-218.
In the Renilla-luciferase assay, we inserted the 3 0 -UTR region of RET in the 3 0 -UTR of Renilla gene in psiCheck2 vector (modified psicheck2 vector). When we transfected the cells with either the modified psicheck2 vector and each pre-miRNA of interest or the modified vector and pre-miR-negative control, we found that five miRNAs (miR-218, miR-128, miR-27b, miR-15a, miR-195) significantly downregulated Renilla translation by binding to the RET 3 0 -UTR region, as observed by a reduction of 41-49% in Renilla activity at 24 hours after transfection (Figure 3a) , indicating that RET is a target of these miRNAs. To further validate these results, we then analyzed RET expression in TPH-1 and HL-60 cell lines, which overexpress RET, by flow cytometry after transfection with each of the five pre-miRNAs. We observed a cell-line-dependent downregulation of RET protein levels after pre-miRNA transfection (Figure 3b ). DISCUSSION t(8;16) AML is a leukemia subtype resulting from the fusion of two genes, MYST3 and CREBBP, with chromatin-modifying properties. 12 Although prior studies have shown that miRNAs may define tumor entities better than microarray expression data from thousands of mRNAs, 18 no previous studies have focused on the miRNA profile of t(8;16) AML. In the present study, we have for the first time identified a specific miRNA signature that characterizes this AML subtype. In addition, as miRNA expression in cancer can be affected by epigenetic changes like DNA methylation and histone modification, 22 which contribute significantly to the leukemogenic phenotype, we analyzed possible mechanisms of epigenetic regulation of the t(8;16) AML miRNA signature, 12 and found that one-third of miRNAs were re-expressed after treatment with epigenetic modification agents. Importantly, we have also validated RET as a target of five miRNAs in the signature. t(8;16) AML showed a highly distinctive, tightly clustered miRNA signature when compared with a wide variety of molecularly defined AML subtypes, confirming its biological uniqueness. Moreover, a specific 47-miRNA signature clearly differentiated t(8;16) AML from other AML subtypes with monocytic differentiation, indicating that the t(8;16) AML miRNA signature was not a result of the characteristic monocytic differentiation of t(8;16) AML.
We observed an overall downregulation of the miRNAs in our t(8;16) signature, some of which have previously been 19, 28 including let-7 family, miR-34a, miR-15a, miR-26a/b and miR-125b. However, our t(8;16) AML miRNA signature also includes downregulated miRNAs that are usually upregulated in other cancers, such as miR-21 and cluster miR-17-92. 29 miR-21 is known to be transcriptionally regulated by STAT3, 30 and we found that STAT3 is downregulated in t(8;16) AML, although the functional consequences of this deregulation are unknown. To further elucidate a potential mechanism of the downregulation of miR-17-92 cluster, we measured the mRNA expression of c-Myc, a transcriptional regulator of miR-17-92 cluster, in t(8;16) AML specimens and did not find significant differences in c-Myc levels.
MYST3 and CREBBP have a role in leukemogenesis, both as partners in MYST3-CREBBP rearrangement and separately with other partners. [31] [32] [33] [34] [35] MYST3 interacts directly with p53 protein, and the p53-MYST3 complex increases after DNA damage, contributing to cell-cycle arrest in G1 phase. 36 MYST3 is essential for self-renewal of hematopoietic stem cells. 37, 38 CREBBP has multiple functions in development and hematopoiesis. 8, 39 Heterozygous inactivation of CREBBP in mice impairs hematopoietic stem cell self-renewal, induces multiple defects in multilineage hematopoietic differentiation, and increases the incidence of hematologic malignances. 40, 41 Interestingly, structural inactivating alterations of CREBBP hamper its p53 acetylation function in some lymphoma subtypes. 10 As 11 of the downregulated miRNAs in our signature are related to p53 refs 42,43 and some of the downregulated miRNAs in our signature, such as miR-34a, are related to DNA damage response, we investigated a possible p53 downregulation in t(8;16) AML, but no differences in p53 mRNA levels in t(8;16) AML compared with other AML subtypes were observed. However, other mechanisms, such as acetylation and phosphorylation, can also affect p53 activity. 44 Interestingly, MYST3-CREBBP fusion protein has been described to inhibit p53-mediated transcription by decreasing p53 acetylation, 36 leading us to hypothesize that the infraexpression of p53-related miRNAs in our t(8;16) AML signature could be in part because of abnormal acetylation of p53. CREBBP mutations have also been found in acute lymphoblastic leukemia, where they impair histone acetylation and transcriptional regulation of CREBBP targets. 10, 11 MYST3 and CREBBP chromosomal rearrangements may deregulate acetylation, leading to a disruption in the balance between proliferation and differentiation during hematopoiesis. This may contribute-at least in part-to the leukemogenic phenotype through epigenetic modifications caused by transcriptional deregulation. 12 In the present study, we have observed a re-expression of several miRNAs after treatment with a demethylating agent. Interestingly, this re-expression was higher when histone deacetylase inhibitor (TSA) was added to the demethylating agent (5 0 -AZA), leading us to speculate that acetylation can have an important role in our downregulated signature. This hypothesis is further supported by the fact that there were no differences in promoter methylation between t(8;16) AML and other cytogenetic subtypes. Previous studies analyzing gene methylation in AML have shown a correlation between determined molecular subtypes and the methylation profile, but not all AML subtypes were associated to a characteristic methylation pattern. 45 Although the experiments on miRNA re-expression after exposure to epigenetic modifying agents could be only performed in one patient due to the lack of additional available samples, we believe that our findings have potential physiopathological implications and warrant validation.
Other well-characterized fusion oncoproteins that arise from chromosomal translocations in AML have been associated with epigenetic silencing of miRNAs, such as miR-repression of miR-223 by AML1-ETO 46 and transcriptional repression of miR-210, miR-23 and miR-24 by PML-RARa. 47 Further study is warranted to clarify whether the fusion protein MYST3-CREBBP is responsible for the specific mechanisms involved in this epigenetic silencing.
RET proto-oncogene encodes one of the tyrosine kinase receptors that transduce signals for cell growth and differentiation. RET mutations have been associated with papillary thyroid carcinoma and multiple endocrine neoplasia type IIA and IIB. 13 Moreover, RET may affect the differentiation or growth of hemopoietic cells. 48, 49 Our group and others 1,2 have observed that RET mRNA is typically overexpressed in t(8;16) AML. In the present study, we have found that RET mRNA expression levels showed a strong inverse correlation with three miRNAs. In addition, four other miRNAs that are downregulated in our signature were also predicted to bind to the 3 0 -UTR region of RET. We therefore investigated if these downregulated miRNAs could explain RET overexpression. The Renilla-luciferase assay showed that miR-218, miR-128, miR-27b, miR-15a and miR-195 target RET, and these results were validated in two cell lines overexpressing RET, TPH-1 and HL-60. Transfection with these miRNAs produced a Figure 3 . Validation of RET as target of t(8;16) miRNA signature. (a) Renilla-luciferase assay at 24 hours after transfection with pre-miRNAs 218, 15a, 128, 27b and 195 showed a significant downregulation (*Po0.05; **Po0.01; ***Po0.001). Pre-miR-135a was included as negative control as no complementarity has been observed between RET 3 0 -UTR sequence and this miRNA. (b) Percentage of RET positive cells, analyzed by flow cytometry, in TPH-1 and HL60 cell lines 24 hours after transfection with pre-miRNAs selected from the Renilla-luciferase assay. In the TPH-1 cell line, the percentage of RET-positive cells was reduced after transfection with three of five pre-miRNAs, whereas a significant reduction of RET expression in HL-60 cell line was observed with four of five miRNAs.
miRNA signature in t(8;16) AML M Díaz-Beyá et al significant downregulation of RET protein in both HL-60 (except miR-27b) and TPH1 (except miR-218 and miR-15a) cell lines. The differences of the specific miRNAs leading to RET downregulation observed between these two cell lines could be attributed to differences in baseline levels of RET protein and diversities in the accessibility to individual miRNA binding sites. These findings functionally validate for the first time the modulation of RET expression by several miRNAs characteristic of t(8;16) AML.
Our unique t(8;16) AML miRNA signature has confirmed the biologic uniqueness of this AML subtype. Its specific clinical features and distinct mRNA signature, together with the miRNA signature reported here indicate that despite its low incidence, t(8;16) AML deserves recognition as a distinct entity in the WHO classification.
In summary, t(8;16) AML harbors a specific miRNA signature characterized mainly by downregulation of multiple miRNAs, some of which are responsible for the high RET levels previously observed in this subtype. Finally, this miRNA signature may be the result of the deregulation of epigenetic machinery in leukemic cells, although the precise mechanisms involved remain to be elucidated.
